Tove Christensen

A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Julian Gold, The Albion Centre, The University of Sydney School of Medicine, Sydney, NSW, Australia
  • ,
  • Monica Marta, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • Ute C Meier, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • Tove Christensen
  • David Miller, Institute of Neurology, University College London, United Kingdom
  • ,
  • Daniel Altmann, Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • ,
  • David Holden, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • Lucia Bianchi, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • Rocco Adiutori, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • David MacManus, Institute of Neurology, University College London, United Kingdom
  • ,
  • Tarek Yousry, Institute of Neurology, University College London, United Kingdom
  • ,
  • Klaus Schmierer, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • Benjamin Turner, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
  • ,
  • Gavin Giovannoni, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
OriginalsprogEngelsk
TidsskriftMultiple Sclerosis and Related Disorders
Vol/bind24
Sider (fra-til)123-128
ISSN2211-0348
DOI
StatusUdgivet - 2018

Se relationer på Aarhus Universitet Citationsformater

ID: 129593752